Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Alligator Bioscience AB (ATORX) NPV

Sell:8.64 SEK Buy:8.65 SEK Change: 0.66 SEK (7.10%)
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
Sell:8.64 SEK
Buy:8.65 SEK
Change: 0.66 SEK (7.10%)
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
Sell:8.64 SEK
Buy:8.65 SEK
Change: 0.66 SEK (7.10%)
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Alligator Bioscience AB is a Sweden-based company that is engaged in development of immunotherapies for the treatment of cancer. The Company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. In the discovery of those drugs, the Company uses its technology platforms ALLIGATOR-GOLD and FIND. ALLIGATOR-GOLD is a library containing human antibodies. FIND (which stands for Fragment Induced Diversity) is an antibody optimization technology. In its pipeline, the Company has thee projects: ADC-1013 (antibody), ATOR-1015 (bispecific immune activating antibody) and ATOR-1016 (bispecific agonistic antibody), which are in research/preclinical stage.

Contact details

Address:
Scheelevagen 2 Byggnad 401
LUND
223 63
Sweden
Telephone:
+46 (46) 2864280
Website:
https://alligatorbioscience.se/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ATORX
ISIN:
SE0000767188
Market cap:
663.91 million SEK
Shares in issue:
71.39 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Peter Benson
    Independent Chairman of the Board
  • Per Norlen
    Chief Executive Officer
  • Marie Svensson
    Chief Financial Officer
  • Malin Carlsson
    Chief Operating Officer
  • Christina Furebring
    Senior Vice President Preclinical Development
  • Peter Ellmark
    Vice President Discovery
  • Anu Balendran
    Vice President Business Development
  • Gayle Mills
    Chief Business Officer
  • Charlotte Russell
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.